Zhitong Finance App News, Ruibo Bio-B (06938.HK) announced that it has submitted a phase I clinical trial application for the company's siRNA product RBD3133 injection targeting INHBE in the European Union to treat overweight and obesity.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Ruibo Bio-B (06938.HK) announced that it has submitted a phase I clinical trial application for the company's siRNA product RBD3133 injection targeting INHBE in the European Union to treat overweight and obesity.